The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Table 4

Costs of medications in thousands € stratified by year and by scenario (with or without denosumab).

	2010		2011		2012		2013
	Without denosumab	With denosumab	Without denosumab	With denosumab	Without denosumab	With denosumab	Without denosumab	With denosumab
Alendronate (Fosamax)	27,859	27,859	26,359	26,359	26,114	26,114	25,959	25,959
Alendronate plus cholecalciferol (Fosavance)	48,040	48,040	49,413	49,092	48,432	47,933	49,513	48,713
Generic alendronate	72,561	72,561	76,132	76,132	80,274	80,274	83,254	83,254
Risedronate (Actonel)	90,527	90,527	57,872	57,872	60,843	60,843	63,888	63,888
Zoledronate (Actonel)	2,940	2,940	4,962	4,962	5,263	5,263	5,421	5,421
Ibandronate oral (Bonviva)	43,313	43,313	51,187	44,209	54,375	43,527	61,116	43,725
Raloxifene (Evista)	6,847	6,847	7,457	7,457	7,688	7,688	7,919	7,919
Strontium ranelate (Protelos)	58,074	58,074	78,835	56,736	93,214	58,858	111,307	56,232
Teriparatide	50,701	50,701	54,415	54,415	57,001	57,001	60,584	60,584
PTH	10,244	10,244	11,070	11,070	11,243	11,243	11,581	11,581